All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Grants Fast Track Designation to CFI-402257 for ER+/HER2– Breast Cancer

January 11th 2023

The FDA has granted a fast track designation to best-in-class threonine tyrosine kinase inhibitor CFI-402257 for the treatment of adult patients with estrogen receptor (ER)–positive/HER2-negative advanced breast cancer after disease progression on prior CDK4/6 inhibitors and endocrine therapy.

Luveltamab Tazevibulin Shows Encouraging Activity in Frα-Selected Advanced Ovarian Cancer

January 11th 2023

Treatment with the folate receptor α–directed antibody-drug conjugate luveltamab tazevibulin led to a 37.5% overall response rate in Frα-selected patients with advanced ovarian cancer, defined by a tumor proportion score above 25%.

Zolbetuximab Aims to Add First-of-Its-Kind Approach to GEJ Cancer Treatment Paradigm

January 11th 2023

The biomarker claudin 18.2 has recently shown promise as an intriguing new target in the gastroesophageal junction adenocarcinoma space.

CTLA-4–Based Combinations Highlight Evolution of Treatment in Metastatic NSCLC

January 11th 2023

Vamsidhar Velcheti, MD, highlights the advancement of CTLA-4–based combinations in non–small cell lung cancer treatment, the emergence of antibody-drug conjugates in non–small cell lung cancer, and the impact of the POSEIDON trial on the treatment landscape.

Adjuvant Pembrolizumab Improves QOL vs Ipilimumab or HDI in Resected Melanoma

January 10th 2023

Treatment with adjuvant pembrolizumab resulted in favorable quality-of-life outcomes vs high-dose interferon α 2b or ipilimumab in patients with resected melanoma at high risk for relapse.

At-Home Screening Test Demonstrates Sensitivity, Specificity in Detecting CRC

January 10th 2023

Geneoscopy’s at-home, stool-based diagnostic screening test to detect colorectal cancer and advanced adenomas in average-risk individuals displayed high sensitivity and specificity, meeting the primary objectives of the phase 3 CRC-PREVENT trial.

Henry Ford Hospital Earns Prestigious Recognition from National Accreditation Program for Rectal Cancer

January 10th 2023

Henry Ford Hospital has earned a three-year accreditation from the National Accreditation Program for Rectal Cancer, which was developed through a collaboration between the OSTRiCh consortium and the Commission on Cancer, a quality program of the American College of Surgeons.

FDA Grants Orphan Drug Designation to Azeliragon for Glioblastoma

January 10th 2023

The FDA has granted an orphan drug designation to azeliragon for the treatment of patients with glioblastoma.

Duvelisib Wins Orphan Drug Designation for PTCL in Europe

January 10th 2023

The European Commission has issued an orphan drug designation to duvelisib for the treatment of adult patients with peripheral T-cell lymphoma.

Crane Helps Fellows Navigate a Fraught Time in Gynecology

January 10th 2023

Erin K. Crane, MD, MPH, talked to Oncology Fellows about helping trainees care for their own health and wellness, navigate the politics surrounding gynecologic care, and the lessons she hopes they take away from the program.

IBI351 Gets Breakthrough Therapy Designation for KRAS G12C–Mutated NSCLC in China

January 10th 2023

The Center for Drug Evaluation of China's National Medical Products Administration has granted a breakthrough therapy designation to IBI351 for the treatment of patients with advanced non–small cell lung cancer harboring a KRAS G12C mutation who have received at least 1 prior line of systemic therapy.

Novel Combination Regimens Strengthen and Expand Treatment Paradigm for Genitourinary Cancers

January 10th 2023

Tanya B. Dorff, MD, highlights improvements in the current treatment paradigm for other genitourinary cancers and spotlights efforts being made to expand the role of immunotherapy and targeted therapy combinations.

FDA Grants Orphan Drug Designation to LP-284 for Mantle Cell Lymphoma

January 9th 2023

The FDA has granted an orphan drug designation to LP-284, a novel small-molecule, next-generation acylfulvene, for the treatment of mantle cell lymphoma

BGB-11417 Shows Encouraging Early Efficacy and Tolerability in CLL

January 9th 2023

Chan Y. Cheah, MD, MBBS, discusses the the phase 1 BGB-11417-101 trial, which showed that the BCL-2 inhibitor BGB-11417, administered alone or in combination with the BTK inhibitor zanubrutinib, induced promising response rates and was well tolerated patients with chronic lymphocytic leukemia.

Oxaliplatin Treatment Duration Potentially Linked With Incidence of Severe Neuropathy in Stage III Colon Cancer

January 9th 2023

Patients with stage III colon cancer who receive longer courses of adjuvant oxaliplatin, exercise for less than 9 hours per week, have diabetes, or have a higher body mass index could experience higher rates of severe oxaliplatin-induced peripheral neuropathy.

Unique Properties of Uproleselan Demonstrates Promise in AML

January 9th 2023

Eunice Wang, MD, highlights the mechanism of action of E-selectin inhibitors and speaks on the safety profile and efficacy of uproleselan in patients with acute myeloid leukemia.

Florida Cancer Specialists & Research Institute Welcomes Madhu Unnikrishnan, MD To Palm Coast Location in Flagler County

January 9th 2023

Florida Cancer Specialists & Research Institute, LLC welcomes Board-certified medical oncologist/hematologist Madhu Unnikrishnan, MD to the statewide practice.

Tovorafenib Elicits Responses in Recurrent or Progressive Pediatric Low-Grade Glioma

January 9th 2023

Tovorafenib monotherapy generated responses in patients with recurrent or progressive pediatric low-grade glioma.

Seismic Change Occurs in Small Bites

January 9th 2023

The Dobbs v Jackson Women’s Health Organization decision, a landmark decision of the US Supreme Court in which the court held that the Constitution of the United States does not confer a right to abortion, will most likely affect your practice.

Real-World Analysis Shows Low Use of Ovarian Suppression in Premenopausal HR+/HER2+ Breast Cancer

January 9th 2023

Maryam Lustberg, MD, MPH, discusses key results from a retrospective analysis of ovarian suppression in HR–positive, HER2-positive breast cancer, the importance of assessing real-world practice patterns, and the need for continued study of other predictive biomarkers for endocrine therapy in this population.